Does the media favor RNAC or CRMD?

In the previous week, Cartesian Therapeutics had 5 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 5 mentions for CorMedix. CorMedix's average media sentiment score of 0.57 beat Cartesian Therapeutics' score of 0.19 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AURA or RNAC?

In the previous week, Cartesian Therapeutics had 7 more articles in the media than Aura Biosciences. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.71 beat Cartesian Therapeutics' score of 0.19 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AVTX or RNAC?

In the previous week, Cartesian Therapeutics had 6 more articles in the media than Avalo Therapeutics. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.88 beat Cartesian Therapeutics' score of 0.19 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DSGN or RNAC?

In the previous week, Cartesian Therapeutics had 8 more articles in the media than Design Therapeutics. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Cartesian Therapeutics' score of 0.19 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANRO or RNAC?

In the previous week, Cartesian Therapeutics had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 1 mentions for Alto Neuroscience. Cartesian Therapeutics' average media sentiment score of 0.19 beat Alto Neuroscience's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cartesian Therapeutics (RNAC) Competitors

$9.51 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$9.58 +0.07 (+0.74%)

As of 06/12/2026 07:20 PM Eastern

Compare

RNAC vs. CRMD, AURA, AVTX, DSGN, and ANRO

Should you buy Cartesian Therapeutics stock or one of its competitors? MarketBeat compares Cartesian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cartesian Therapeutics include CorMedix (CRMD), Aura Biosciences (AURA), Avalo Therapeutics (AVTX), Design Therapeutics (DSGN), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry.

How does Cartesian Therapeutics compare to CorMedix?

Cartesian Therapeutics (NASDAQ:RNAC) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Cartesian Therapeutics presently has a consensus price target of $32.60, suggesting a potential upside of 242.80%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 71.62%. Given Cartesian Therapeutics' higher probable upside, equities research analysts plainly believe Cartesian Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CorMedix has a net margin of 45.25% compared to Cartesian Therapeutics' net margin of -8,550.65%. CorMedix's return on equity of 45.57% beat Cartesian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
CorMedix	45.25%	45.57%	24.76%

Cartesian Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

In the previous week, Cartesian Therapeutics had 5 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 5 mentions for CorMedix. CorMedix's average media sentiment score of 0.57 beat Cartesian Therapeutics' score of 0.19 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	99.79	-$130.30M	-$5.90	N/A
CorMedix	$311.71M	2.20	$163.05M	$2.13	4.10

Summary

CorMedix beats Cartesian Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Cartesian Therapeutics had 7 more articles in the media than Aura Biosciences. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.71 beat Cartesian Therapeutics' score of 0.19 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences has higher earnings, but lower revenue than Cartesian Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Cartesian Therapeutics	$2.80M	99.79	-$130.30M	-$5.90	N/A

Aura Biosciences currently has a consensus target price of $20.50, suggesting a potential upside of 219.81%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 242.80%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aura Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aura Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

Cartesian Therapeutics beats Aura Biosciences on 10 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Avalo Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Avalo Therapeutics currently has a consensus price target of $46.67, suggesting a potential upside of 216.17%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 242.80%. Given Cartesian Therapeutics' higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Avalo Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	12,932.22	-$78.26M	-$5.46	N/A
Cartesian Therapeutics	$2.80M	99.79	-$130.30M	-$5.90	N/A

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cartesian Therapeutics had 6 more articles in the media than Avalo Therapeutics. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.88 beat Cartesian Therapeutics' score of 0.19 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalo Therapeutics beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Cartesian Therapeutics had 8 more articles in the media than Design Therapeutics. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Cartesian Therapeutics' score of 0.19 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Design Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 50.41%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 242.80%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Design Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Cartesian Therapeutics	$2.80M	99.79	-$130.30M	-$5.90	N/A

Design Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Summary

Design Therapeutics and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alto Neuroscience has higher earnings, but lower revenue than Cartesian Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Cartesian Therapeutics	$2.80M	99.79	-$130.30M	-$5.90	N/A

Alto Neuroscience has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Alto Neuroscience has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 63.46%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 242.80%. Given Cartesian Therapeutics' higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Cartesian Therapeutics had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 1 mentions for Alto Neuroscience. Cartesian Therapeutics' average media sentiment score of 0.19 beat Alto Neuroscience's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cartesian Therapeutics beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$279.40M	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.61	20.00	23.99	24.42
Price / Sales	99.79	305.33	511.38	110.47
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-1.96	8.32	10.65	6.82
Net Income	-$130.30M	$23.94M	$3.57B	$337.56M
7 Day Performance	62.29%	1.84%	0.58%	1.17%
1 Month Performance	28.86%	-0.04%	1.54%	3.16%
1 Year Performance	-8.73%	44.82%	25.40%	30.58%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	2.7211 of 5 stars	$9.51 flat	$32.60 +242.8%	-8.7%	$279.40M	$2.80M	N/A	64	Analyst Upgrade Gap Down High Trading Volume
CRMD CorMedix	3.4333 of 5 stars	$8.65 +1.3%	$15.00 +73.4%	-40.0%	$669.98M	$311.71M	4.06	30	Gap Up
AURA Aura Biosciences	2.5618 of 5 stars	$6.35 -2.0%	$20.50 +222.8%	-0.2%	$669.95M	N/A	N/A	50	Gap Down
AVTX Avalo Therapeutics	3.35 of 5 stars	$12.90 +1.3%	$48.13 +273.1%	+205.0%	$669.68M	$60K	N/A	40	Analyst Forecast Gap Down
DSGN Design Therapeutics	2.9976 of 5 stars	$10.55 +0.9%	$16.50 +56.4%	+185.7%	$653.30M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. CRMD, AURA, AVTX, DSGN, and ANRO

How does Cartesian Therapeutics compare to CorMedix?

Summary

How does Cartesian Therapeutics compare to Aura Biosciences?

Summary

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Summary

How does Cartesian Therapeutics compare to Design Therapeutics?

Summary

How does Cartesian Therapeutics compare to Alto Neuroscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. CRMD, AURA, AVTX, DSGN, and ANRO

How does Cartesian Therapeutics compare to CorMedix?

Do analysts prefer RNAC or CRMD?

Do institutionals & insiders have more ownership in RNAC or CRMD?

Is RNAC or CRMD more profitable?

Which has more volatility and risk, RNAC or CRMD?

Does the media favor RNAC or CRMD?

Which has preferable valuation and earnings, RNAC or CRMD?

Summary

How does Cartesian Therapeutics compare to Aura Biosciences?

Does the media favor AURA or RNAC?

Which has better earnings and valuation, AURA or RNAC?

Do analysts recommend AURA or RNAC?

Is AURA or RNAC more profitable?

Do insiders & institutionals believe in AURA or RNAC?

Which has more risk & volatility, AURA or RNAC?

Summary

How does Cartesian Therapeutics compare to Avalo Therapeutics?

Which has more volatility and risk, AVTX or RNAC?

Is AVTX or RNAC more profitable?

Do analysts prefer AVTX or RNAC?

Which has preferable earnings & valuation, AVTX or RNAC?

Do institutionals & insiders believe in AVTX or RNAC?

Does the media refer more to AVTX or RNAC?

Summary

How does Cartesian Therapeutics compare to Design Therapeutics?

Does the media favor DSGN or RNAC?

Do analysts recommend DSGN or RNAC?

Do institutionals and insiders hold more shares of DSGN or RNAC?

Which has preferable earnings & valuation, DSGN or RNAC?

Which has more volatility & risk, DSGN or RNAC?

Is DSGN or RNAC more profitable?

Summary

How does Cartesian Therapeutics compare to Alto Neuroscience?

Do insiders and institutionals hold more shares of ANRO or RNAC?

Which has stronger valuation & earnings, ANRO or RNAC?

Which has more volatility and risk, ANRO or RNAC?

Is ANRO or RNAC more profitable?

Do analysts prefer ANRO or RNAC?

Does the media favor ANRO or RNAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools